Is hypofractionated radiotherapy used to treat soft tissue sarcomas? Assessment of practices using the NETSARC network.

Emma Agnoux, Anaïs Stefani, Nassim Sahki, Émilie Meknaci, Maria Jolnerovski
{"title":"Is hypofractionated radiotherapy used to treat soft tissue sarcomas? Assessment of practices using the NETSARC network.","authors":"Emma Agnoux, Anaïs Stefani, Nassim Sahki, Émilie Meknaci, Maria Jolnerovski","doi":"10.1016/j.canrad.2024.05.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Extremity soft-tissue sarcomas are treated by wide surgical resection with normofractionated radiotherapy. Over the past 3years, several phase II trials emerged on perioperative hypofractionated radiotherapy. We aimed to review the current practice in France and Luxembourg of hypofractionated radiotherapy as curative treatment for extremity soft-tissue sarcomas.</p><p><strong>Materials and methods: </strong>We sent an electronic adaptive survey to sarcoma radiation oncologists at 28 centres in France and the Grand Duchy of Luxembourg belonging to the NETSARC network. The questionnaire was distributed via the NETSARC mailing list in December 2021 and January 2022. It consisted of four to nine questions with closed multiple choice, or open-ended (short or long) answers. Some questions assessed agreement with proposals for pre- or postoperative hypofractionated radiotherapy for extremity soft-tissue sarcomas.</p><p><strong>Results: </strong>Of the 28 radiation oncologists surveyed, 11 (39.2 %) from nine centres responded. Of these, 55 % used hypofractionated radiotherapy, mainly for elderly and frail patients. The main reason why hypofractionated radiotherapy was not used was the lack of scientific evidence and therapeutic habits.</p><p><strong>Conclusion: </strong>Hypofractionated radiotherapy for extremity soft-tissue sarcomas remains to be investigated in high-powered studies but could be offered in the future for well-selected patients by a multidisciplinary board in a sarcoma referral centre.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.canrad.2024.05.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Extremity soft-tissue sarcomas are treated by wide surgical resection with normofractionated radiotherapy. Over the past 3years, several phase II trials emerged on perioperative hypofractionated radiotherapy. We aimed to review the current practice in France and Luxembourg of hypofractionated radiotherapy as curative treatment for extremity soft-tissue sarcomas.

Materials and methods: We sent an electronic adaptive survey to sarcoma radiation oncologists at 28 centres in France and the Grand Duchy of Luxembourg belonging to the NETSARC network. The questionnaire was distributed via the NETSARC mailing list in December 2021 and January 2022. It consisted of four to nine questions with closed multiple choice, or open-ended (short or long) answers. Some questions assessed agreement with proposals for pre- or postoperative hypofractionated radiotherapy for extremity soft-tissue sarcomas.

Results: Of the 28 radiation oncologists surveyed, 11 (39.2 %) from nine centres responded. Of these, 55 % used hypofractionated radiotherapy, mainly for elderly and frail patients. The main reason why hypofractionated radiotherapy was not used was the lack of scientific evidence and therapeutic habits.

Conclusion: Hypofractionated radiotherapy for extremity soft-tissue sarcomas remains to be investigated in high-powered studies but could be offered in the future for well-selected patients by a multidisciplinary board in a sarcoma referral centre.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低分次放射治疗是否用于治疗软组织肉瘤?利用NETSARC网络对实践进行评估。
目的:治疗四肢软组织肉瘤的方法是进行大范围手术切除,同时进行正常分次放疗。过去 3 年中,出现了几项关于围手术期低分量放疗的 II 期试验。我们的目的是回顾法国和卢森堡目前将超分割放疗作为治疗四肢软组织肉瘤的方法:我们向隶属于NETSARC网络的法国和卢森堡大公国28个中心的肉瘤放射肿瘤专家发送了一份电子自适应调查问卷。问卷于2021年12月和2022年1月通过NETSARC邮件列表发布。问卷包括四至九个问题,答案为封闭式多选或开放式(长或短)。其中一些问题评估了对四肢软组织肉瘤术前或术后低分次放射治疗建议的同意程度:结果:在接受调查的 28 位放射肿瘤学家中,来自 9 个中心的 11 位(39.2%)做出了回答。其中,55%的放射肿瘤科医生采用了低分次放射治疗,主要用于年老体弱的患者。未使用低分次放射治疗的主要原因是缺乏科学证据和治疗习惯:结论:针对四肢软组织肉瘤的低剂量放射治疗仍有待高功率研究的检验,但未来可由肉瘤转诊中心的多学科委员会为经过严格筛选的患者提供低剂量放射治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Is hypofractionated radiotherapy used to treat soft tissue sarcomas? Assessment of practices using the NETSARC network. Management of unilateral neck irradiation in elderly patients with head and neck cancer: Which place for hypofractionation? A single-centre experience of 43 patients. Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Permanent alopecia after radiotherapy of primary brain tumours: The most influential factors. Safety of concurrent trastuzumab-emtansine and radiation therapy for breast cancer: Single-centre experience from a morbidity and mortality review meetings procedure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1